Inventiva/$IVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Ticker
$IVA
Sector
Primary listing
Employees
73
Headquarters
Website
Inventiva Metrics
BasicAdvanced
$726m
-
-$2.16
0.88
-
Price and volume
Market cap
$726m
Beta
0.88
52-week high
$7.98
52-week low
$2.85
Average daily volume
841k
Financial strength
Current ratio
3.159
Quick ratio
1.408
Long term debt to equity
-696.238
Total debt to equity
-809.515
Interest coverage (TTM)
-0.66%
Profitability
EBITDA (TTM)
-150.831
Gross margin (TTM)
99.67%
Net profit margin (TTM)
-5,237.95%
Operating margin (TTM)
-2,085.70%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$102,450
Management effectiveness
Return on assets (TTM)
-45.08%
Return on equity (TTM)
523.99%
Valuation
Price to revenue (TTM)
82.765
Price to book
-20.8
Price to tangible book (TTM)
-20.67
Price to free cash flow (TTM)
-5.323
Free cash flow yield (TTM)
-18.79%
Free cash flow per share (TTM)
-0.641
Growth
Revenue change (TTM)
-52.03%
Earnings per share change (TTM)
-38.48%
3-year revenue growth (CAGR)
-27.92%
10-year revenue growth (CAGR)
-0.88%
3-year earnings per share growth (CAGR)
13.13%
10-year earnings per share growth (CAGR)
7.98%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs